69 results about "RNA marker" patented technology

The invention discloses a prognostic Lnc RNA (ribonucleic acid) marker used for predicting liver cancer. The lnc RNA marker is an RNA selected from one or more of MKLN1-AS, RP11-133K1.6, RP1-228H13.5, LRRC3-AS1 and AC127904.2. Meanwhile, the invention discloses a prognostic risk scoring model for predicting the liver cancer, and patients are subjected to risk assessment and monitoring according to the model serving as supplementary means to predict prognosis of the patients with liver cancer.

Methods are described in which a sample containing RNA is contacted with an enzyme having an RNA ligation activity in the presence of a labeled substrate to provide labeled RNA. Methods of performing an array analysis of a labeled RNA sample are also described.

The invention discloses an application of fluorescent carbon dots in living cell nucleolus imaging or RNA labeling or display. The fluorescent carbon dots adopt red light emitting fluorescent carbon dots with an up-and-down conversion function, and particularly adopt fluorescent carbon dots disclosed in the CN104263366A. In some embodiments, the living cell nucleolus imaging can be accomplished by the use of the fluorescent carbon dots through cell culture, dye solution preparation, staining and imaging. With the help of the fluorescent carbon dots, the living cell nucleolus imaging or labeling or display of RNA in living cells can be realized, and the fluorescent carbon dots have the advantages of high selectivity on nucleolus imaging, high imaging resolution, simpliness, rapidness, low cost, low biological toxicity, and quite high practical value.

The invention provides a fluorescent dye with nitrobenzimidazole as an RNA (ribonucleic acid) recognition group as well as a preparation method and application of the fluorescent dye. The fluorescent dye with the nitrobenzimidazole as the RNA recognition group has the structure represented by the general formula I, wherein D is a chromophoric group of the dye; the parent of D is selected from a naphthalimide dye, an essence dye, a rhodamine dye, a fluorescein dye, an anthracene pyridine dye or a perylene bisimide dye. The invention also provides application of the fluorescent dye with the nitrobenzimidazole as the RNA recognition group in specific RNA labeling in a biological sample. The fluorescent dye disclosed by the invention has high-efficiency and specific RNA recognition capacity and also has high-efficiency two-photon absorption capacity; furthermore, the fluorescent dye is low in photoinduced toxicity, biological toxicity and light bleaching performance.

The invention belongs to the field of biotechnology and neurocognitive and relates to a serum / plasma micro-RNA marker for detecting patients with mild cognitive impairment and an application thereof. The maker is any one or a combination of miR-206 and miRNA-132. The marker is applied in diagnosis of patients with mild cognitive impairment, and the marker is applied in preparation of a kit for diagnosis of patients with mild cognitive impairment. According to the application of the marker, content of serum / plasma miR-206 and / or miRNA-132 of a testee is detected by a real-time fluorescence quantitative polymerase chain reaction (Real-time PCR) method, and the content of the testee is compared with that of a normal cognitive subject to diagnose mild cognitive impairment. The screened miRNA marker has cognitive impairment specificity, is simple to operate diagnosis of mild cognitive impairment, has high sensitivity and is suitable for large-scale screening.

Methods are described in which a sample containing RNA is contacted with an enzyme having an RNA ligation activity in the presence of a labeled substrate to provide labeled RNA. Methods of performing an array analysis of a labeled RNA sample are also described.

RNA molecules are an important member of an intracellular genetic information delivery system. Conventional RNA labeling methods cannot simultaneously have the characteristics of living cells, no invasion, high temporal and spatial resolution, single molecules, etc., so a novel method for labeling and tracking RNA need to be developed. The invention discloses a novel labeling method for messengerRNA and circular RNA based on self-ligation label bimolecular fluorescence complementation. A RNA aptamer subsystem is cooperatively used, aptamers are inserted at proper positions in the RNA, and twoparts of a self-ligation label are respectively fused with the binding proteins of the RNA aptamers. When the fusion proteins do not bind to RNA, RNA molecules do not fluoresce; when and only when the fusion proteins bind to RNA, the RNA molecules fluoresce, so the fluorescence background of an intracellular RNA marker is reduced. The novel RNA labeling method based on self-ligation label bimolecular fluorescence complementation can be used for long-term interference-free single-molecule imaging observation and tracking of messenger RNA and circular RNA of living cells and fixed cells, and has good application prospects in cell biology.

The invention discloses a long chain noncoding RNA marker for auxiliary diagnosis of colorectal cancer (CRC). Long chain noncoding RNA is HOTAIR; auxiliary diagnosis or prediction of patient conditiondevelopment of the CRC can be realized by detecting expression quantity of the long chain noncoding RNA; differentiation, infiltration depth, proliferation and metastasis conditions of the CRC can bepredicted by monitoring expression conditions of p21 and a value of judging prognosis is realized. Expression level of LncRNA HOTAIR gene can be detected by RT-qPCR, real-time quantitative PCR, immunodetection, in-situ hybridization, chip or a high-throughput sequencing platform; meanwhile, the invention also discloses silencing HOTAIR which can obviously inhibit the proliferation, migration andinvasion abilities of CRC cells, reduce the expression of PCNA, Ki67, cyclin E and CDK2 and medicate expression increase of p21. The invention provides a molecular marker for the CRC and provides theoretical basis for mechanism research and clinical individualized therapy of the CRC; a brand-new treatment strategy can be provided for clinically treating the CRC by monitoring the expression of theLncRNA HOTAIR in the CRC.

The invention provides long-chain non-coding RNA and application thereof. Studies suggest that expression of LOC102724660 in lung adenocarcinoma tissue is obviously different from expression in para-carcinoma tissue. On this basis, it is concluded that LOC102724660 can serve as a molecular marker for diagnosing lung adenocarcinoma. Based on the fact that LOC102724660 is expressed at a low level in lung adenocarcinoma tissue and is over-expressed in lung adenocarcinoma cells, the function of LOC102724660 in lung adenocarcinoma is researched, and the result show that overexpression of LOC102724660 can inhibit the proliferation of lung adenocarcinoma cells remarkably. The key role of LOC102724660 in the lung adenocarcinoma pathogenesis is disclosed, and a novel molecular marker and drug target are provided for clinical diagnosis, treatment and prognosis monitoring of lung adenocarcinoma.

The present invention relates to methods for characterizing the pathological state of the kidney, methods of characterizing an agent, methods of evaluating the kidney protective and therapeutic characteristics of an agent and methods of monitoring the effect of a pharmaceutical agent on the kidney of a subject, related to measuring a kidney RNA marker in the urine of a subject.

The invention discloses a method for synthesizing a quenching fluorescence RNA marker and a method for detecting food-borne pathogenic bacteria. The synthesis method comprises the following steps: synthesizing up-conversion nanoparticles with amino modification by adopting a one-step solvothermal method; combining specific RNA with a quencher to synthesize an RNA fluorescent marker; and connecting the RNA fluorescent marker with the up-conversion nanoparticles with amino modification by adopting a glutaraldehyde crosslinking method so as to obtain the quenching fluorescence RNA marker. In addition, the quenching fluorescence RNA marker is applied to the detection of food-borne pathogenic bacteria. The detection comprises the following steps: accurately cutting a specific nucleic acid target in trace pathogenic bacteria cells by using nuclease Cas13a, shearing the quenching fluorescence RNA marker by utilizing the incidental cutting effect of the nuclease, and releasing fluorescence which can be detected; and collecting fluorescence spectrum data, and constructing a quantitative detection model of fluorescence intensity change values and different amounts of food-borne pathogenic bacteria nucleic acid targets so as to realize nano fluorescence trace detection of food-borne pathogenic bacteria nucleic acid.

The present invention is directed to the assessment of transmissible spongiform encephalopathy (TSE) using a sample from a living individual. The assessment is based on the use of an RNA marker molecule in a sample of whole blood. The RNA encodes a hypothetical cystein protease. The invention is further directed to the detection of the marker molecule by means of real-time PCR. The invention provides the use of the nucleotide sequence as a marker in the assessment of TSE, a method for assessing bovine spongiform encephalopathy (BSE) in a bovine animal as well as kits to practice the invention.

The invention relates to a symbolic micro RNA marker for detecting a spermatogenic failure passage effect and application thereof, belongs to the field of biotechnology and reproductive medicine, and discloses a micro RNA (miRNA) marker for detecting a spermatogenic failure passage effect and application thereof. The marker is a plurality selected from a group consisting of rho-miR-1-3p, rho-miR-124-3p and rho-miR-190a-5p. The marker has specificity and sensitivity for monitoring the spermatogenic failure passage effect, provides a reliable detection basis and quick detection method for diagnosis monitoring of the spermatogenic failure passage effect and has important application values.

The invention relates to an RNA-dependent RNA-polymerase, to methods and kits for marking and / or amplifying in a primary dependent or independent manner a ribonucleic acid (RNA), in particular a viral, eucaryontic, procaryontic and double-stranded ribonucleic acid (RNA) for the biological and medical use thereof. Said RNA-dependent RNA-polymerase comprises a right-hand conformation and the amino acid sequence the following sequence sections: a. XXDYS b. GXPSG c. YGDD d. XXYGL e. XXXXFLXRXX having the following significances: D: aspartate Y: tyrosine S: serine G: glicine P: proline L: leucine F: phenylalanine R: arginine X: any amino acid. The inventive amplifying method is particularly suitable for microarray engineering, siRNA production and for diagnosticating viral infections by detecting viral RNA in patient samples. The inventive marking method is particularly suitable for purifying RNA by means of affinity bonds and for marking RNA used in molecular biology methods for characterising the function and / or structure of a viral, eucaryontic, procaryontic and double-stranded ribonucleic acid (RNA).

The invention relates to a long-chain non-coding RNA marker for early diagnosis of malignant melanoma and application thereof. The long-chain non-coding RNA marker is Linc01296 with a corresponding DNA sequence as shown in SEQ. ID. NO. 1. The application is an application of the long-chain non-coding RNA marker Linc01296 in the preparation of an early diagnosis reagent for malignant melanoma as atarget RNA. According to the invention, lcnRNA, Linc0126, with abnormal expression in serum of malignant melanoma is successfully screened, and expression of Linc01296 is significantly high in the serum of malignant melanoma patients. In addition, Linc01296 can effectively distinguish malignant melanoma patients from healthy people and patients with benign skin moles. The marker has high sensitivity and specificity, wherein the sensitivity can reach 84.69%, the specificity can reach 88.77%, and the marker has high diagnostic characteristics.

The invention discloses a long-chain non-coding RNA marker for diagnosing and treating hepatocellular carcinoma. Specifically, the long-chain non-coding RNA marker is LINC01419. The invention discloses an application of LINC01419 in preparation of a product for diagnosing hepatocellular carcinoma and a pharmaceutical composition for treating hepatocellular carcinoma. The invention also discloses akit for diagnosing hepatocellular carcinoma and a pharmaceutical composition for treating hepatocellular carcinoma. The kit provided by the invention can be used as one of the means for early diagnosis of hepatocellular carcinoma. The pharmaceutical composition disclosed by the invention has a relatively good inhibition effect on hepatocellular carcinoma, and has important reference and practicalsignificance in treatment of hepatocellular carcinoma.

The invention discloses a kit, a device and a method for lung cancer diagnosis. The kit comprises exosome long RNA markers, including one or more of LRRC37A2, TLE4, AZI2, MRPL9, YPEL2, RAB3GAP1, TBC1D23, STK3, IL1B, HMGN1, ERI3, HOPX, CDA, CCBL2, TBK1, RAD54L2, ARPC5, GIMAP5, PLA2G1B, SNHG5 and RPL21. The lung cancer detection method based on the exosome long RNA markers has high sensitivity and high specificity in early lung cancer, and provides an important value for early diagnosis of lung cancer, thereby providing a great help to the prevention and treatment of lung cancer in China.

The invention relates to the field of biological detection, in particular to molecular detection of organisms, more particularly to a group of exosome RNA markers associated with colorectal adenoma and an application thereof.

The invention relates to the field of biological detection, in particular to biological molecular detection and a combination of exosome RNA markers related to colorectal cancer and application of thecombination of the exosome RNA markers related to colorectal cancer.

The invention discloses an application of miRNA 200 cluster as a marker for diagnosing and / or treating Alzheimer's disease. The invention provides application of miRNA 200 cluster micro RNA in diagnosis and treatment of Alzheimer's disease. AD model cells, AD model animals, naturally aged animals and clinical serum samples are used; the expression quantity of the miRNA 200 cluster in a human bodyis detected by using a primer aiming at the miRNA 200 cluster micro RNA marker; it is found that the expression of miRNA 200-cluster micro RNA in the Alzheimer's disease process is significantly reduced; Abeta generation, tau protein excessive phosphorylation and apoptosis-like degeneration in AD lesion are changed by targeting BACE1 and PRKACB, so that miRNA 200 cluster micro RNA can be used as anew Alzheimer's disease marker for auxiliary diagnosis and treatment of Alzheimer's disease.

The invention discloses a micro-RNA marker and application thereof to preparation of a product for the diagnosis of a chronic thromboembolic pulmonary hypertension CTEPH disease. The micro-RNA markeris hsa-miR-20a-5p. The invention further discloses a kit; the kit contains a reagent for determining the has-miR-20a-5p marker. The kit for chronic thromboembolic pulmonary hypertension CTEPH miRNA disease detection is quick and convenient and can realize the early diagnosis and the prediction of CTEPH.

The invention discloses a CRISPR-Cas13 nucleic acid detection kit based on a lightening type RNA aptamer. The kit comprises the lightening type RNA aptamer, Cas13 protein, crRNA and nucleic acid dye; the lightening type RNA aptamer can be combined with nucleic acid dye to emit fluorescence, and if the lightening type RNA aptamer is sheared by Cas13 protein, fluorescence is quenched; the crRNA is a section of RNA, the crRNA and Cas13 protein can form a crRNA-Cas13 compound, and after the Cas 13-crRNA is combined with a target RNA sequence, the enzyme digestion activity of the Cas13 protein is activated, and an RNA aptamer is excised. The kit can detect living pathogens and RNA markers by detecting RNA, and compared with an existing nucleic acid detection method based on CRISPR-Cas13, the method does not depend on reverse transcription and nucleic acid amplification, target RNA sequence detection is completed in one step, the detection cost is low, the operation steps are simple, high specificity and sensitivity can be guaranteed, and industrial application is facilitated.

The invention discloses a circRNA marker for liver cancer diagnosis. The circRNA marker is circ-104075. Experiments prove that circRNA-104075 highly expresses in serum of liver cancer patients, expression of the circRNA-104075 is positively adjusted by HNF4a in liver cancer cells, the circRNA-104075 stimulates YAP expression through adsorbing mir-582-3p, the level of the circ-104075 in the liver cancer patients is higher than normal individuals and other disease patients, and the circ-104075 is high in specificity expression in liver cancer. AUC-ROC analysis proves that the serum circ-104075 is higher in diagnosis efficiency when being compared with other non-coded RNA markers, so that circ-104075 can serve as a novel liver cancer diagnosis marker.

The invention relates to a mi RNA marker related to side effects of platinum-based chemotherapy to advanced non-small cell lung cancer (NSCLC) patients and application and related kit thereof. The marker is hsa-mir-196ars11614913 and can be used in detection or prognoses of the side effects of platinum-based chemotherapy to the advanced NSCLC patients, thereby the marker can provide a basis for the individualistic drug therapy to the advanced NSCLC patients.

The invention discloses a micro-RNA marker and application thereof to preparation of a product for the diagnosis of a chronic thromboembolic pulmonary hypertension CTEPH disease. The micro-RNA markeris hsa-miR-20a-5p. The invention further discloses a kit; the kit contains a reagent for determining the has-miR-20a-5p marker. The kit for chronic thromboembolic pulmonary hypertension CTEPH miRNA disease detection is quick and convenient and can realize the early diagnosis and the prediction of CTEPH.

The invention discloses a peripheral blood circular RNA marker for noninvasive diagnosis of active pulmonary tuberculosis. A primer is designed according to the peripheral blood circular RNA marker; the designed primer can be used for preparing a noninvasive diagnosis kit used for the active pulmonary tuberculosis. The peripheral blood circular RNA marker can be used for effectivelydistinguishing patients with pulmonary tuberculosis from healthy people, and has the advantages of convenient and noninvasive detection, high accuracy and good stability, thus being suitable for being popularized and used.

The invention relates to a constructing method of a transcription expression gene model of a ultraconserved region of peripheral blood mononuclear cells of systemic lupus erythematosus, and applications of the transcription expression gene model. The constructing method includes: a step of setting an SLE group and a normal control with each group comprising a plurality of whole blood samples, and separating to obtain peripheral blood mononuclear cells; a step of measuring the content, the quality and the integrity of the sample RNA and determining that the sample RNA can be used for the next step; a step of analyzing the T-UCRs expression level of human bodies by adoption of a T-UCR chip, and detecting UCRs labeled by a gene specific probe; a step of performing RNA labeling and chip hybridization; a step of analyzing the chip scanning results by a feature extraction method; a step of indentifying differentially-expressed RNA transcriptons of latent T-UCRs and overlapping UCRs of the latent T-UCRs by adoption of FC filtration, and measuring the functions of the differential mRNA related to the UCRs in biological processes by adoption of GO analysis; and a step of comparing changes of the multiple among the samples in the two group and screening the differentially-expressed RNA.

The present invention relates to methods for characterizing the pathological state of the kidney, methods of characterizing an agent, methods of evaluating the kidney protective and therapeutic characteristics of an agent and methods of monitoring the effect of a pharmaceutical agent on the kidney of a subject, related to measuring a kidney RNA marker in the urine of a subject.

The invention discloses a biomarker group for sepsis, a sepsis judgment method and a kit. The biomarker group is composed of new biomarkers different from an existing RNA markers. When sepsis diagnosis is carried out, through an established index system of the biomarker group, the score of the expression quantity of the biomarker group of a measured subject is judged, so as to identify and stratify the sepsis patient, and provide clues for understanding the main pathophysiological mechanism and the potential targeted therapy approach of a single patient.

The invention discloses application of a serum exosome has_circ_0004771 in preparation of a diagnostic reagent for the alcohol dependence syndrome (AD). According to the application, by studying changes of the expression of circ RNA in a serum exosome of a patient with the alcohol dependence syndrome, the circ RNA with the most prominent significance is screened out, and when applied to clinical detection of the AD, the circ RNA achieves the specific effectiveness. The serum exosome has_circ_0004771 achieves the high value of diagnosing the AD, the expression level of the serum exosome has_circ_0004771 is related to the severity degree of the AD, and the serum exosome has_circ_0004771 can be taken as a marker for AD diagnosis and evaluation of the severity degree of the AD. Through the serum circ RNA marker and development and application of diagnostic kits, diagnosis for the AD can be more convenient and easy to implement, the foundation is laid for quickly and accurately mastering the illness state of the patient by a clinician and improving the clinical treatment effect, and assistance is provided for discovery of novel small molecule drug targets with the potential treatment value.